JP6585625B2 - 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト - Google Patents

先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト Download PDF

Info

Publication number
JP6585625B2
JP6585625B2 JP2016565135A JP2016565135A JP6585625B2 JP 6585625 B2 JP6585625 B2 JP 6585625B2 JP 2016565135 A JP2016565135 A JP 2016565135A JP 2016565135 A JP2016565135 A JP 2016565135A JP 6585625 B2 JP6585625 B2 JP 6585625B2
Authority
JP
Japan
Prior art keywords
nbi
receptor antagonist
crf
acth
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016565135A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017503030A5 (enExample
JP2017503030A (ja
Inventor
ディミトリ イー． グリゴリアディス，
ディミトリ イー． グリゴリアディス，
Original Assignee
ニューロクライン バイオサイエンシーズ，インコーポレイテッド
ニューロクライン バイオサイエンシーズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52450623&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6585625(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ニューロクライン バイオサイエンシーズ，インコーポレイテッド, ニューロクライン バイオサイエンシーズ，インコーポレイテッド filed Critical ニューロクライン バイオサイエンシーズ，インコーポレイテッド
Publication of JP2017503030A publication Critical patent/JP2017503030A/ja
Publication of JP2017503030A5 publication Critical patent/JP2017503030A5/ja
Priority to JP2019043466A priority Critical patent/JP6936825B2/ja
Application granted granted Critical
Publication of JP6585625B2 publication Critical patent/JP6585625B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2016565135A 2014-01-21 2015-01-21 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト Active JP6585625B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019043466A JP6936825B2 (ja) 2014-01-21 2019-03-11 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461929941P 2014-01-21 2014-01-21
US61/929,941 2014-01-21
US201461981033P 2014-04-17 2014-04-17
US61/981,033 2014-04-17
US201462069155P 2014-10-27 2014-10-27
US62/069,155 2014-10-27
PCT/US2015/012315 WO2015112642A1 (en) 2014-01-21 2015-01-21 Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019043466A Division JP6936825B2 (ja) 2014-01-21 2019-03-11 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト

Publications (3)

Publication Number Publication Date
JP2017503030A JP2017503030A (ja) 2017-01-26
JP2017503030A5 JP2017503030A5 (enExample) 2018-03-01
JP6585625B2 true JP6585625B2 (ja) 2019-10-02

Family

ID=52450623

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016565135A Active JP6585625B2 (ja) 2014-01-21 2015-01-21 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト
JP2019043466A Active JP6936825B2 (ja) 2014-01-21 2019-03-11 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト
JP2020099865A Active JP7104743B2 (ja) 2014-01-21 2020-06-09 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト
JP2021184620A Withdrawn JP2022010260A (ja) 2014-01-21 2021-11-12 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト
JP2024079330A Pending JP2024098001A (ja) 2014-01-21 2024-05-15 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019043466A Active JP6936825B2 (ja) 2014-01-21 2019-03-11 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト
JP2020099865A Active JP7104743B2 (ja) 2014-01-21 2020-06-09 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト
JP2021184620A Withdrawn JP2022010260A (ja) 2014-01-21 2021-11-12 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト
JP2024079330A Pending JP2024098001A (ja) 2014-01-21 2024-05-15 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト

Country Status (24)

Country Link
US (5) US20170020877A1 (enExample)
EP (2) EP4450070A1 (enExample)
JP (5) JP6585625B2 (enExample)
KR (2) KR102258522B1 (enExample)
CN (2) CN111228274A (enExample)
AU (4) AU2015209452C1 (enExample)
BR (1) BR112016016975B1 (enExample)
CA (2) CA3155599A1 (enExample)
DK (1) DK3096756T3 (enExample)
ES (1) ES2984706T3 (enExample)
FI (1) FI3096756T3 (enExample)
HR (1) HRP20241046T1 (enExample)
HU (1) HUE068315T2 (enExample)
IL (5) IL304134B2 (enExample)
LT (1) LT3096756T (enExample)
MX (3) MX389004B (enExample)
NZ (1) NZ722122A (enExample)
PL (1) PL3096756T3 (enExample)
PT (1) PT3096756T (enExample)
RS (1) RS65839B1 (enExample)
RU (1) RU2718918C2 (enExample)
SI (1) SI3096756T1 (enExample)
SM (1) SMT202400361T1 (enExample)
WO (1) WO2015112642A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3155599A1 (en) 2014-01-21 2015-07-30 Neurocrine Biosciences, Inc. Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
WO2015127288A1 (en) 2014-02-20 2015-08-27 Alder Biopharmaceuticals, Inc. Anti-acth antibodies and use thereof
CN109906222B (zh) 2016-09-07 2023-08-01 加利福尼亚大学董事会 减少p-tau并且改善认知的变构促肾上腺皮质激素释放因子受体1(crfr1)拮抗剂
BR112020002967A2 (pt) 2017-08-14 2020-08-11 Spruce Biosciences, Inc. antagonistas de receptor de fator de liberação de corticotropina
CN112423747A (zh) * 2018-04-27 2021-02-26 云杉生物科学公司 用于治疗睾丸肾上腺残余瘤和卵巢肾上腺残余瘤的方法
JP7532328B2 (ja) * 2018-12-07 2024-08-13 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 先天性副腎過形成を処置するためのｃｒｆ１受容体アンタゴニスト、その医薬製剤および固体形態
MA56226A (fr) * 2018-12-07 2022-04-20 Neurocrine Biosciences Inc Antagoniste du récepteur crf1, formulations pharmaceutiques et ses formes solides pour le traitement de l'hyperplasie surrénale congénitale
KR20220052927A (ko) 2019-07-19 2022-04-28 스프루스 바이오사이언시스 인코포레이티드 선천성 부신 증식증의 치료 방법
CN118252829A (zh) * 2019-09-27 2024-06-28 纽罗克里生物科学有限公司 Crf受体拮抗剂及使用方法
CN116096373A (zh) * 2020-06-10 2023-05-09 纽罗克里生物科学有限公司 用于治疗先天性肾上腺增生症的crf1受体拮抗剂
EP4656192A2 (en) 2020-08-12 2025-12-03 Spruce Biosciences, Inc. Tildacerfont and derivatives thereof for treating polycystic ovary syndrome
MD20210019A2 (ro) 2021-04-12 2022-10-31 Максим МАСЮТИН Metodă de tratament a hiperplaziei suprarenale congenitale, cauzate de deficit de 21-hidroxilază cu debut tardiv prin regimul de glucocorticoizi adaptat individual
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4949582B1 (enExample) 1969-01-20 1974-12-27
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
FR2692893B1 (fr) 1992-06-24 1994-09-02 Sanofi Elf Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
US6664261B2 (en) 1996-02-07 2003-12-16 Neurocrine Biosciences, Inc. Pyrazolopyrimidines as CRF receptor antagonists
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
US6159980A (en) 1996-09-16 2000-12-12 Dupont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
FR2754258B1 (fr) 1996-10-08 1998-12-31 Sanofi Sa Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
KR20000069311A (ko) 1997-04-22 2000-11-25 디르크 반테 Ｃｒｆ 길항성 퀴노- 및 퀴나졸린
AU9021598A (en) 1997-08-22 1999-03-16 Du Pont Pharmaceuticals Company Nitrogen substituted imidazo{4,5-c}pyrazoles as corticotropin relea sing hormone antagonists
US6531475B1 (en) 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
WO2000059888A1 (en) 1999-04-02 2000-10-12 Neurogen Corporation N-benzimidazolylmethyl- and n-indolylmethyl-benzamides and their use as crf modulators
FR2796380B3 (fr) 1999-07-15 2001-08-17 Sanofi Synthelabo Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant
FR2802530B1 (fr) 1999-12-17 2002-02-22 Sanofi Synthelabo Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant
US7276526B2 (en) 2001-07-13 2007-10-02 Bristol-Myers Squibb Pharma Company Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands
EP1718311A1 (en) 2004-02-13 2006-11-08 Pfizer Products Incorporated Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
EP1781257B1 (en) 2004-08-13 2018-12-19 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
US7652035B2 (en) 2004-10-19 2010-01-26 Neurocrine Bioscience, Inc. CRF receptor antagonists and methods relating thereto
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
EP1869049B1 (en) 2005-03-21 2009-03-04 Eli Lilly And Company Imidazopyridazine compounds
WO2006107784A1 (en) 2005-04-05 2006-10-12 Eli Lilly And Company Imidazopyridazine compounds
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
JPWO2006126718A1 (ja) 2005-05-27 2008-12-25 田辺三菱製薬株式会社 ピラゾロピリミジン誘導体
US8828392B2 (en) 2005-11-10 2014-09-09 Topotarget Uk Limited Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent
WO2007069565A1 (ja) 2005-12-12 2007-06-21 Ono Pharmaceutical Co., Ltd. 二環式複素環化合物
US20100184771A1 (en) 2005-12-15 2010-07-22 Ono Pharmaceutical Co., Ltd. Bicyclic Heterocyclic Compound
DK1982178T3 (da) 2006-02-07 2013-09-08 Phenoquest Ag Fremgangsmåder til behandling af affektbetonede lidelser
EP1834641A1 (en) 2006-03-16 2007-09-19 Sanofi-Aventis Use of CRF1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia
BRPI0711872A2 (pt) 2006-05-22 2011-12-06 Vanda Pharmaceuticals Inc tratamento para distúrbios depressivos
CN101516886B (zh) 2006-09-20 2012-02-29 伊莱利利公司 噻吩吡唑并嘧啶化合物
JP5161226B2 (ja) * 2006-09-20 2013-03-13 イーライ リリー アンド カンパニー Ｃｒｆ１受容体アンタゴニストとしてのチアゾールピラゾロピリミジン
WO2008051533A2 (en) 2006-10-25 2008-05-02 Takeda Pharmaceutical Company Limited Benzimidazole compounds
WO2008083070A1 (en) 2006-12-29 2008-07-10 Neurogen Corporation Crf1 receptor ligands comprising fused bicyclic heteroaryl moieties
EP2125753A1 (en) 2006-12-29 2009-12-02 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds having crf antagonistic activity
TW200902019A (en) 2007-04-26 2009-01-16 Ono Pharmaceutical Co Dicyclic heterocyclic compound
WO2009008552A1 (en) 2007-07-11 2009-01-15 Taisho Pharmaceutical Co., Ltd. 8-aryl-4-alkylpyrrolo[2,3,4-de]quinolin-5(4h)-one and 8-aryl-4-alkyl-4,5-dihydropyrrolo[2,3,4-de]quinolin-5-ol derivatives
WO2009144632A1 (en) 2008-05-30 2009-12-03 Pfizer Limited Novel compounds
WO2010014687A1 (en) 2008-07-31 2010-02-04 Bristol-Myers Squibb Company Substituted carbamate derivatives as modulators of corticotropin-releasing factor receptor activity
US7932256B2 (en) 2008-07-31 2011-04-26 Bristol-Myers Squibb Company (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity
US7994203B2 (en) 2008-08-06 2011-08-09 Novartis Ag Organic compounds
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
EP2352449B1 (en) 2008-11-03 2018-02-21 Synthes GmbH Adjustable rod assembly
WO2010096426A2 (en) 2009-02-20 2010-08-26 Emory University Compounds, compositions, methods of synthesis, and methods of treatment
HUP0900267A2 (en) 2009-04-30 2011-03-28 Sanofi Aventis Process for preparing of thiazole amines and intermediates thereof
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
JPWO2011043387A1 (ja) 2009-10-08 2013-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロオキサゾール化合物
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
US8835444B2 (en) 2010-02-02 2014-09-16 Novartis Ag Cyclohexyl amide derivatives as CRF receptor antagonists
CN104768555B (zh) 2012-04-13 2018-10-30 Epizyme股份有限公司 用于治疗癌症的联合治疗
US20150278438A1 (en) * 2012-04-23 2015-10-01 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Genetic predictors of response to treatment with crhr1 antagonists
EP2841068B8 (en) 2012-04-23 2019-03-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Crhr1 antagonists for use in the treatment of patients having crh overactivity
CA3155599A1 (en) * 2014-01-21 2015-07-30 Neurocrine Biosciences, Inc. Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
WO2016065177A1 (en) 2014-10-22 2016-04-28 The Trustees Of The University Of Pennsylvania Method of treating depression and other stress related disorders
MX375718B (es) 2015-02-06 2025-03-06 Neurocrine Biosciences Inc [9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos.
AU2016240213B2 (en) 2015-04-02 2022-01-27 HMNC Holding GmbH Method of treatment using genetic predictors of a response to treatment with CRHR1 antagonists
WO2018012066A1 (ja) * 2016-07-14 2018-01-18 株式会社コナミデジタルエンタテインメント ゲームシステム、端末装置及びプログラム
WO2018102552A1 (en) 2016-11-30 2018-06-07 Case Western Reserve University Combinations of 15-pgdh inhibitors with corcosteroids and/or tnf inhibitors and uses thereof
WO2018219804A1 (en) 2017-06-02 2018-12-06 Bayer Pharma Aktiengesellschaft Self-microemulsifying drug delivery systems
KR102644781B1 (ko) 2017-08-14 2024-03-06 스프루스 바이오사이언시스 인코포레이티드 코티코트로핀 방출 인자 수용체 길항제
BR112020002967A2 (pt) 2017-08-14 2020-08-11 Spruce Biosciences, Inc. antagonistas de receptor de fator de liberação de corticotropina
CN112423747A (zh) 2018-04-27 2021-02-26 云杉生物科学公司 用于治疗睾丸肾上腺残余瘤和卵巢肾上腺残余瘤的方法
MA56226A (fr) 2018-12-07 2022-04-20 Neurocrine Biosciences Inc Antagoniste du récepteur crf1, formulations pharmaceutiques et ses formes solides pour le traitement de l'hyperplasie surrénale congénitale
KR20220052927A (ko) 2019-07-19 2022-04-28 스프루스 바이오사이언시스 인코포레이티드 선천성 부신 증식증의 치료 방법
CN118252829A (zh) 2019-09-27 2024-06-28 纽罗克里生物科学有限公司 Crf受体拮抗剂及使用方法
ES3039926T3 (en) 2019-12-04 2025-10-27 Neurocrine Biosciences Inc Crf receptor antagonists and methods of use
CN116096373A (zh) 2020-06-10 2023-05-09 纽罗克里生物科学有限公司 用于治疗先天性肾上腺增生症的crf1受体拮抗剂
US20240024330A1 (en) 2020-08-26 2024-01-25 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use

Also Published As

Publication number Publication date
DK3096756T3 (da) 2024-08-05
KR102258522B1 (ko) 2021-05-31
AU2015209452A1 (en) 2016-08-04
SMT202400361T1 (it) 2024-11-15
RU2016133972A3 (enExample) 2018-09-26
HRP20241046T1 (hr) 2024-11-08
JP7104743B2 (ja) 2022-07-21
IL296683B2 (en) 2023-12-01
RU2020112197A (ru) 2020-05-21
IL296683A (en) 2022-11-01
IL304134B1 (en) 2024-12-01
EP3096756A1 (en) 2016-11-30
IL296683B1 (en) 2023-08-01
IL246783B (en) 2021-10-31
JP6936825B2 (ja) 2021-09-22
LT3096756T (lt) 2024-08-26
AU2022263460A1 (en) 2022-12-08
US20210361659A1 (en) 2021-11-25
KR20160106176A (ko) 2016-09-09
US11311544B2 (en) 2022-04-26
MX2021012539A (es) 2021-11-12
RU2718918C2 (ru) 2020-04-15
AU2022263460B2 (en) 2024-10-17
AU2015209452B2 (en) 2020-05-07
IL304134B2 (en) 2025-04-01
WO2015112642A1 (en) 2015-07-30
EP3096756B1 (en) 2024-06-12
FI3096756T3 (fi) 2024-08-14
AU2020207774B2 (en) 2022-08-04
CA3155599A1 (en) 2015-07-30
US11730739B2 (en) 2023-08-22
NZ722122A (en) 2020-06-26
RU2016133972A (ru) 2018-03-05
AU2015209452C1 (en) 2020-11-05
JP2017503030A (ja) 2017-01-26
ES2984706T3 (es) 2024-10-30
IL304134A (en) 2023-09-01
JP2022010260A (ja) 2022-01-14
KR20210064407A (ko) 2021-06-02
MX389004B (es) 2025-03-20
CN106102740A (zh) 2016-11-09
PL3096756T3 (pl) 2024-10-28
AU2020207774A1 (en) 2020-08-06
RS65839B1 (sr) 2024-09-30
US10905690B2 (en) 2021-02-02
SI3096756T1 (sl) 2024-09-30
MX2022000080A (es) 2022-02-03
IL246783A0 (en) 2016-08-31
AU2024219813A1 (en) 2024-10-10
HUE068315T2 (hu) 2024-12-28
BR112016016975B1 (pt) 2022-12-27
MX2016009499A (es) 2017-02-27
US20210137926A1 (en) 2021-05-13
IL317035A (en) 2025-01-01
JP2019081814A (ja) 2019-05-30
US20190231781A1 (en) 2019-08-01
US20170020877A1 (en) 2017-01-26
BR112016016975A2 (pt) 2017-08-08
CN111228274A (zh) 2020-06-05
JP2020138978A (ja) 2020-09-03
CA2936974A1 (en) 2015-07-30
US20240058342A1 (en) 2024-02-22
EP4450070A1 (en) 2024-10-23
JP2024098001A (ja) 2024-07-19
IL286782A (en) 2021-10-31
PT3096756T (pt) 2024-08-26

Similar Documents

Publication Publication Date Title
JP6585625B2 (ja) 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト
HK40116454A (en) Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
RU2812318C2 (ru) Антагонисты рецептора cfr1 для лечения врожденной гиперплазии коры надпочечников
HK40030956A (en) Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
HK1231749B (en) Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
HK1231749A1 (en) Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
EP1842543A1 (en) Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190311

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190813

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190905

R150 Certificate of patent or registration of utility model

Ref document number: 6585625

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250